Evolocumab（ACS/急性冠症候群）：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22
4 Disease Management 24
4.1 Treatment Overview 24
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54
8 Evolocumab (AMG 145) 59
8.1 Overview 59
8.2 Efficacy 61
8.3 Safety 65
8.4 Dosing and Formulation 65
8.5 Potential Clinical Positioning 66
8.6 Potential Commercial Positioning 66
8.7 Pricing and Reimbursement 66
8.8 SWOT Analysis 67
8.9 Forecast 67
9 Appendix 69
9.1 Bibliography 69
9.2 Abbreviations 75
9.3 Methodology 79
9.4 Forecasting Methodology 79
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 79
9.4.2 Diagnosed Acute Coronary Syndrome Patients 80
9.4.3 Percent Drug-Treated Patients 81
9.4.4 General Pricing Assumptions 81
9.4.5 Generic Erosion 83
9.4.6 Pricing of Pipeline Agents 83
9.5 Physicians and Specialists Included in this Study 84
9.6 About the Authors 87
9.6.1 Author 87
9.6.2 Reviewer 87
9.6.3 Global Head of Healthcare 88
9.7 About GlobalData 89
9.8 Disclaimer 89